Sugi Predict

Sugi Predict / Targets / SMURF2

SMURF2

E3 ubiquitin-protein ligase SMURF2 · Q9HAU4 · SMURF2 on Sugi Atlas →

430 patent compounds predicted against SMURF2, 265 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17261668 SCHEMBL17261668 1.00 18/20
SCHEMBL17261692 SCHEMBL17261692 1.00 18/20
SCHEMBL18682983 SCHEMBL18682983 1.00 18/20
SCHEMBL17261607 SCHEMBL17261607 0.87 18/20
SCHEMBL17261622 SCHEMBL17261622 0.85 18/20
SCHEMBL17261651 SCHEMBL17261651 0.83 18/20
SCHEMBL17261608 SCHEMBL17261608 1.00 17/20
SCHEMBL17261611 SCHEMBL17261611 1.00 17/20
SCHEMBL17261612 SCHEMBL17261612 1.00 17/20
SCHEMBL17261616 SCHEMBL17261616 1.00 17/20
SCHEMBL17261617 SCHEMBL17261617 1.00 17/20
SCHEMBL17261625 SCHEMBL17261625 1.00 17/20
SCHEMBL17261626 SCHEMBL17261626 1.00 17/20
SCHEMBL17261630 SCHEMBL17261630 1.00 17/20
SCHEMBL17261640 SCHEMBL17261640 1.00 17/20
SCHEMBL17261646 SCHEMBL17261646 1.00 17/20
SCHEMBL17261649 SCHEMBL17261649 1.00 17/20
SCHEMBL17261659 SCHEMBL17261659 1.00 17/20
SCHEMBL17261665 SCHEMBL17261665 1.00 17/20
SCHEMBL17261669 SCHEMBL17261669 1.00 17/20

Clinical trials — most relevant to SMURF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Smurf2 Gene Expression in Urinary Tract Tumors nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Genetic Factors Affecting the Severity of Beta Thalassemia nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Molecular Profile of the Evolution of Inclusion Body Myositis nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SMURF2 binder may also engage these)

ProteinNameSimilarity
Q2TAS2 — 1.000 Q2TAS2 →
A2A5Z6 — 1.000 A2A5Z6 →
Q9PUN2 — 1.000 Q9PUN2 →
A9JRZ0 — 1.000 A9JRZ0 →
SMURF1 E3 ubiquitin-protein ligase SMURF1 1.000 landscape →
Q9CUN6 — 0.999 Q9CUN6 →
Q9DBH0 — 0.999 Q9DBH0 →
Q9N2Z7 — 0.997 Q9N2Z7 →
Q62940 — 0.997 Q62940 →
Q8C863 — 0.996 Q8C863 →
B8N7E5 — 0.996 B8N7E5 →
Q2UBP1 — 0.995 Q2UBP1 →
Q9H0M0 — 0.995 Q9H0M0 →
Q96PU5 — 0.994 Q96PU5 →
P46935 — 0.994 P46935 →
Q5RBF2 — 0.994 Q5RBF2 →
Q9UTG2 — 0.994 Q9UTG2 →
Q92462 — 0.993 Q92462 →
O00308 — 0.993 O00308 →
Q8CFI0 — 0.993 Q8CFI0 →
Q9Y0H4 — 0.992 Q9Y0H4 →
Q8BZZ3 — 0.992 Q8BZZ3 →
P39940 — 0.992 P39940 →
G0S9J5 — 0.991 G0S9J5 →
A1D3C5 — 0.991 A1D3C5 →
Q4WTF3 — 0.990 Q4WTF3 →
B0XQ72 — 0.990 B0XQ72 →
Q0CCL1 — 0.990 Q0CCL1 →
A1CQG2 — 0.990 A1CQG2 →
Q757T0 — 0.989 Q757T0 →